- Home
- GENC vs GOSS Comparison
GENC vs GOSS Comparison
Compare GENC & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENC
- GOSS
- Stock Information
- Founded
- GENC 1894
- GOSS 2015
- Country
- GENC United States
- GOSS United States
- Employees
- GENC N/A
- GOSS N/A
- Industry
- GENC Construction/Ag Equipment/Trucks
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- GENC Industrials
- GOSS Health Care
- Exchange
- GENC Nasdaq
- GOSS Nasdaq
- Market Cap
- GENC 204.9M
- GOSS 203.3M
- IPO Year
- GENC N/A
- GOSS 2019
- Fundamental
- Price
- GENC $13.79
- GOSS $1.11
- Analyst Decision
- GENC
- GOSS Strong Buy
- Analyst Count
- GENC 0
- GOSS 4
- Target Price
- GENC N/A
- GOSS $7.75
- AVG Volume (30 Days)
- GENC 19.9K
- GOSS 1.6M
- Earning Date
- GENC 06-13-2025
- GOSS 05-15-2025
- Dividend Yield
- GENC N/A
- GOSS N/A
- EPS Growth
- GENC 35.02
- GOSS N/A
- EPS
- GENC 1.11
- GOSS N/A
- Revenue
- GENC $113,116,000.00
- GOSS $124,590,000.00
- Revenue This Year
- GENC N/A
- GOSS N/A
- Revenue Next Year
- GENC N/A
- GOSS $190.37
- P/E Ratio
- GENC $12.48
- GOSS N/A
- Revenue Growth
- GENC 5.44
- GOSS N/A
- 52 Week Low
- GENC $10.80
- GOSS $0.50
- 52 Week High
- GENC $24.88
- GOSS $1.55
- Technical
- Relative Strength Index (RSI)
- GENC 56.24
- GOSS 51.87
- Support Level
- GENC $13.40
- GOSS $1.12
- Resistance Level
- GENC $14.49
- GOSS $1.20
- Average True Range (ATR)
- GENC 0.62
- GOSS 0.09
- MACD
- GENC 0.02
- GOSS -0.00
- Stochastic Oscillator
- GENC 53.02
- GOSS 50.41
About GENC Gencor Industries Inc.
Gencor Industries Inc and its subsidiaries is a manufacturer of heavy machinery used in the production of highway construction materials and environmental control equipment. The Company has one reporting segment, equipment for the highway construction industry. The firm's principal products include asphalt plants, combustion systems, hot mix asphalt plants, fluid heat transfer systems, and asphalt pavers.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.